Institute of Myologie Newsletter #86
The most recent newsletter from the Institute of Myologie is available. Among many other themes…
July 21, 2021
Search criteria
Read the post
July 2021 Newsletter ERN Exchange Programme 2021-2022
“The ERN Exchange Programme was designed to share knowledge and stimulate collaboration between healthcare professionals…
Orphanet July 2021 Newsletter “Orphanews”
This month’s Orphanews has an editorial about “Building a better future for rare diseases: campaigns…
ERN-RND for Rare Neurological Diseases July 2021 newsletter
The ERN-RND July 2021 newsletter talks about the ERN-RND Annual Meeting, contains information about, webinars,…
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Although the main outcome measure of the trial was not met (“Changes in DUX4-driven gene…
FSHD European Trial Network (FSHD ETN) Newsletter – July 2021
The July 2021 newsletter of FSHD European Trial Network is now available. Click the link…
June 2021 EJPRD Newsletter
Themes of the EJPRD June 2021 Newsletter: Resource Finder Demonstration Resource Webinar: Human Pluripotent Stem…
The website of the International Myositis Society: imyos.org
The International Myositis Society (iMyoS) has been established in 2019. The main goal of the…
ENMC Themed Workshops: “Post-Covid-19: Issues and opportunities for the neuromuscular field!”
ENMC has started a new initiative of “Themed Workshops”. Due to the fact that we…
Online Work Group and Board Meetings Monday May 31st – Friday 4th June 2021
AGENDA European Reference Network for Rare Neuromuscular Diseases Online Work Group and Board Meetings Monday…
Euro-NMD Board Members Meeting 4th June 2021 – programme and working groups
Dear members of the Board, Affiliated Partners, Executive Committee and Patient Advisory Board, You are…
FSHD European Trial Network
EURO-NMD is pleased to announce the establishment of the “FSHD European Trial Network”. Nicol Voermans…